Tumor Biology

, Volume 36, Issue 6, pp 4633–4642 | Cite as

SYF2 is upregulated in human epithelial ovarian cancer and promotes cell proliferation

  • Sujuan Yan
  • Yan Deng
  • Yong Qiang
  • Qinghua Xi
  • Rong Liu
  • Shuyun Yang
  • Jian Liu
  • Chunhui Tang
  • Jianxin Zhong
  • Yingying Wang
Research Article


SYF2 is reported to be as a cell cycle regulator at the G1/S transition and encodes a nuclear protein that interacts with cyclin-D-type binding protein 1. In our study, we investigated the role of SYF2 in human epithelial ovarian cancer (EOC) progression. Western blot and immunohistochemistry analysis displayed that SYF2 was overexpressed in EOC tissues and EOC cell lines. In addition, the immunoreactivity of SYF2 was positively correlated with tumor grade and Ki-67 expression. In vitro, serum starvation-refeeding experiment and SYF2-siRNA transfection assay demonstrated that the expression of SYF2 was promoted in the proliferative progression of EOC cells, while knockdown of SYF2 expression decreased and inhibited cell growth rate of EOC cells. With all the results, we support that SYF2 might contribute to EOC progression via modulation of proliferation in EOC cells and would provide a novel therapeutic target of human EOC.


Epithelial ovarian cancer (EOC) SYF2 Proliferation Prognosis 



This work was supported by the National Natural Science Foundation of China (No. 81302285).

Conflict of interest



  1. 1.
    Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–81. doi: 10.1016/j.ejca.2009.12.014.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–49. doi: 10.3322/caac.20006.CrossRefPubMedGoogle Scholar
  3. 3.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi: 10.3322/caac.21166.CrossRefPubMedGoogle Scholar
  4. 4.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi: 10.3322/caac.20138.CrossRefPubMedGoogle Scholar
  5. 5.
    Vaughan S, Coward JI, Bast Jr RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11(10):719–25. doi: 10.1038/nrc3144.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol. 2003;1:66. doi: 10.1186/1477-7827-1-66.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Chu PC, Yang YC, Lu YT, Chen HT, Yu LC, Chang MS. Silencing of p29 affects DNA damage responses with UV irradiation. Cancer Res. 2006;66(17):8484–91. doi: 10.1158/0008-5472.CAN-05-3229.CrossRefPubMedGoogle Scholar
  8. 8.
    Chang MS, Chang CL, Huang CJ, Yang YC. p29, a novel GCIP-interacting protein, localizes in the nucleus. Biochem Biophys Res Commun. 2000;279(2):732–7. doi: 10.1006/bbrc.2000.3992.CrossRefPubMedGoogle Scholar
  9. 9.
    Dahan O, Kupiec M. Mutations in genes of Saccharomyces cerevisiae encoding pre-mRNA splicing factors cause cell cycle arrest through activation of the spindle checkpoint. Nucleic Acids Res. 2002;30(20):4361–70.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Chen CH, Chu PC, Lee L, Lien HW, Lin TL, Fan CC, et al. Disruption of murine mp29/Syf2/Ntc31 gene results in embryonic lethality with aberrant checkpoint response. PLoS One. 2012;7(3):e33538. doi: 10.1371/journal.pone.0033538.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Vincent K, Wang Q, Jay S, Hobbs K, Rymond BC. Genetic interactions with CLF1 identify additional pre-mRNA splicing factors and a link between activators of yeast vesicular transport and splicing. Genetics. 2003;164(3):895–907.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Chu PC, Wang TY, Lu YT, Chou CK, Yang YC, Chang MS. Involvement of p29 in DNA damage responses and Fanconi anemia pathway. Carcinogenesis. 2009;30(10):1710–6. doi: 10.1093/carcin/bgp204.CrossRefPubMedGoogle Scholar
  13. 13.
    Ma W, Stafford LJ, Li D, Luo J, Li X, Ning G, et al. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis. J Cell Biochem. 2007;100(6):1376–86. doi: 10.1002/jcb.21140.CrossRefPubMedGoogle Scholar
  14. 14.
    Cui X, Liu Y, Wan C, Lu C, Cai J, He S, et al. Decreased expression of SERPINB1 correlates with tumor invasion and poor prognosis in hepatocellular carcinoma. J Mol Histol. 2014;45(1):59–68. doi: 10.1007/s10735-013-9529-0.CrossRefPubMedGoogle Scholar
  15. 15.
    Song W, Hu L, Li W, Wang G, Li Y, Yan L, et al. Oncogenic Fli-1 is a potential prognostic marker for the progression of epithelial ovarian cancer. BMC Cancer. 2014;14(1):424. doi: 10.1186/1471-2407-14-424.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zhu J, Ji L, Zhang J, Yang L, Guan C, Wang Y, et al. Upregulation of SYF2 in esophageal squamous cell carcinoma promotes tumor cell proliferation and predicts poor prognosis. Tumour Biol J Int Soc Oncodev Biol Med. 2014. doi: 10.1007/s13277-014-2305-2.Google Scholar
  17. 17.
    Guo J, Yang L, Huang J, Liu X, Qiu X, Tao T, et al. Knocking down the expression of SYF2 inhibits the proliferation of glioma cells. Med Oncol. 2014;31(8):101. doi: 10.1007/s12032-014-0101-x.CrossRefPubMedGoogle Scholar
  18. 18.
    Xu W, Cao M, Zheng H, Tan X, Li L, Cui G, et al. Upregulation of SYF2 is associated with neuronal apoptosis caused by reactive astrogliosis to neuroinflammation. J Neurosci Res. 2014;92(3):318–28. doi: 10.1002/jnr.23312.CrossRefPubMedGoogle Scholar
  19. 19.
    Chang MS, Chen CY, Yeh HI, Fan CC, Huang CJ, Yang YC. Cloning, expression, and genomic organization of mouse mp29 gene. Biochem Biophys Res Commun. 2002;299(2):241–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Morris GF, Mathews MB. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem. 1989;264(23):13856–64.PubMedGoogle Scholar
  21. 21.
    Pisani P, Parkin DM, Bray F, Ferlay J. Erratum: Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83, 18-29 (1999). International journal of cancer Journal international du cancer. 1999;83(6):870-3.Google Scholar
  22. 22.
    Aris A. Endometriosis-associated ovarian cancer: A ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res. 2010;3:2. doi: 10.1186/1757-2215-3-2.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cho H, Shin HY, Kim S, Kim JS, Chung JY, Chung EJ, et al. The role of S100A14 in epithelial ovarian tumors. Oncotarget. 2014;5(11):3482–96.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Ben-Yehuda S, Dix I, Russell CS, McGarvey M, Beggs JD, Kupiec M. Genetic and physical interactions between factors involved in both cell cycle progression and pre-mRNA splicing in Saccharomyces cerevisiae. Genetics. 2000;156(4):1503–17.PubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Sujuan Yan
    • 1
    • 3
  • Yan Deng
    • 2
  • Yong Qiang
    • 4
  • Qinghua Xi
    • 2
  • Rong Liu
    • 5
  • Shuyun Yang
    • 6
  • Jian Liu
    • 2
  • Chunhui Tang
    • 2
  • Jianxin Zhong
    • 2
  • Yingying Wang
    • 1
  1. 1.Department of Pathogen Biology, Medical College, Jiangsu Provice Key Laboratory for Information and Molecular Drug TargetNantong UniversityNantongChina
  2. 2.Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong UniversityNantong UniversityNantongChina
  3. 3.Department of Obstetrics and GynecologyThe First People’s Hospital of JingmenJingmenChina
  4. 4.Department of General SurgeryThe First People’s Hospital of JingmenJingmenChina
  5. 5.Department of Oncology, Nantong University Cancer HospitalNantong UniversityNantongChina
  6. 6.Department of Pathology, Nantong University Cancer HospitalNantong UniversityNantongChina

Personalised recommendations